The randomized controlled trial enrolled fifty‑five young women who met screening thresholds for analogue Generalized Anxiety Disorder using the Psychiatric Diagnostic Screening Questionnaire GAD subscale and the Penn State Worry Questionnaire. The cohort's mean age was 21.8 ± 2.2 years, as reported in the abstract. Participants were randomized to two eight‑week interventions following a two‑week familiarization period. The authors declared no competing interests.
Randomization was used to allocate participants between the two arms. The abstract provides the primary screening criteria, age data, and total sample size; the source did not report additional trial flow details such as dropout counts, allocation concealment method, or randomization sequence generation beyond what is presented in the abstract.
Investigators contrasted a guideline‑based progressive, moderate‑to‑high‑intensity resistance exercise training programme (PRET) with a low‑intensity attention‑control sham (SHAM). PRET was described as following World Health Organization and American College of Sports Medicine recommendations and employed progressive loading at approximately 70–80% one‑repetition maximum (1RM). Participants performed two sets of 8–12 repetitions across eight exercises. The SHAM condition used a substantially lower load (around 20% 1RM). Both arms completed a two‑week familiarization prior to the eight‑week intervention.
The abstract lists intensity and set/rep targets for PRET and an approximate 1RM percentage for the SHAM. Detailed exercise selection, session frequency, session duration, supervision level, and adherence rates were not reported in the abstract.
Depressive symptoms served as the primary outcome and were measured with the 16‑item QIDS at five time points: baseline, post‑familiarization, week 4, week 8 (end of intervention), and one‑month follow‑up. The statistical analysis used a two (group) by five (time‑point) repeated measures ANOVA to evaluate group‑by‑time differences. The study team also reported standardized mean differences (SMD) to quantify within‑condition changes and Hedges' d to express between‑group differences in change.
The abstract supplies the test statistics for the group × time interaction (including F and p values) and reports effect estimates with 95% confidence intervals. The source did not provide further statistical model details, such as adjustments for baseline covariates or handling of missing data, within the abstract text.
Data indicated no statistically significant group × time interaction for depressive symptoms (F reported in abstract; p = 0.806). The between‑group effect size for the change in depressive symptoms was small (Hedges' d = 0.17, 95% CI –0.36 to 0.70), a range that crosses the null.
Within each arm, investigators observed large‑magnitude reductions in depressive symptoms. PRET yielded an SMD of 1.53 (95% CI: 0.92 to 2.13). The SHAM arm also showed a large within‑condition reduction, with an SMD of 1.04 (95% CI: 0.49 to 1.60). These within‑condition effect sizes were reported for the intervention period and indicate clinically meaningful symptom declines in both groups.
The authors interpreted the pattern as evidence that both higher‑intensity and lower‑intensity resistance protocols produced antidepressant benefits in this sample. They noted numerically larger within‑condition effects for PRET, but emphasized that superiority versus SHAM was unconfirmed based on the non‑significant interaction and modest between‑group effect size reported in the abstract.
Follow‑up assessment at one month after the intervention showed maintenance of symptom improvement in both groups. The abstract reports maintained effect sizes at follow‑up: PRET SMD = 1.64 (95% CI: 1.02 to 2.26) and SHAM SMD = 1.15 (95% CI: 0.59 to 1.72). The persistence of large within‑condition effects suggests that reductions in depressive symptoms were not transient within the short follow‑up window reported.
Details such as relapse rates, longer‑term durability beyond one month, and potential mediators of sustained response were not provided in the abstract.
The abstract reports no declaration of competing interests. It does not present adverse event rates, safety monitoring procedures, or intolerance leading to withdrawal. The sample was restricted to young women with analogue GAD screening thresholds; generalizability to clinical GAD populations, to men, or to older adults is therefore uncertain based on the abstract alone.
Key unanswered questions remain: the abstract does not detail participant flow or attrition, session adherence or fidelity metrics, blinding procedures for outcome assessors, or prespecified secondary outcomes. The mechanisms driving improvement in the low‑intensity SHAM arm are not explored in the abstract text. Additional trial details and full results would need to be consulted in the full article for a complete appraisal of internal validity, safety, and generalizability.